TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18972301

Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pressurized metered-dose inhaler
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control groups (spacer and water gargle)
Number of subjects: 37
Study: 16432268

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) administered sublingually
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) administered normally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard oral tablet (SOT)
Number of subjects: 10
Study: 12635388

Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dolasetron 12.5 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 118
Study: 10963985

Group type: EXPERIMENTAL
Intervention: First episode schizophrenia (FES) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study: 8601566

Group type: EXPERIMENTAL
Intervention: MAB + MTX (methotrexate, 50 mg/m2/week)
Number of subjects: 53

Group type: COMPARATOR
Intervention: MAB (orchiectomy followed by flutamide therapy)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MAB + MTX
Number of subjects: 53

Group type: COMPARATOR
Intervention: MAB
Number of subjects: 53
Study: 1595921

Group type: EXPERIMENTAL
Intervention: Brandt Anesthesia Tube
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mallinckrodt endotracheal tube
Number of subjects: 48
Study: 6430328

Group type: EXPERIMENTAL
Intervention: Inhaled lactose-free sodium cromoglycate powder (C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study: 31300595

Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexmedetomidine (100 µg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study: 30347801

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMO) composition in breast milk
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 3′‐sialyllactose and 6′‐sialyllactose levels
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Various HMOs
Number of subjects: 106
Study: 25868831

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 64589

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 64589

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 64589
Study: 24046070

Group type: EXPERIMENTAL
Intervention: Plasma IDH1 levels in patients with NSCLC
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: IDH1 for lung adenocarcinoma diagnosis
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Combination of IDH1 with CEA, CA125, and Cyfra21‐1
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Plasma IDH1 levels
Number of subjects: 1422
Study: 21460737

Group type: EXPERIMENTAL
Intervention: Traditional cross‐wiring technique
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lateral cross‐wiring technique
Number of subjects: 29
Study: 19584895

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g ALA from 30 g flaxseed oil)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ground flaxseed (6 g ALA from 30 g ground flaxseed)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no flaxseed intervention)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation
Number of subjects: 2
Study: 17416366

Group type: EXPERIMENTAL
Intervention: Internet-based personal health record
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study: 15029102

Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg x 2/die)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glimepiride (2 mg/die)
Number of subjects: 14
Study: 11499122

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 719

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 719
Study: 9876888

Group type: EXPERIMENTAL
Intervention: Atraumatic needle (22-gauge)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional needle (20-gauge)
Number of subjects: 99
Study: 9198495

Group type: EXPERIMENTAL
Intervention: T2-weighted turbo spin echo (T2-TSE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted SE sequences with fat-suppression
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unenhanced fat-suppressed T1-weighted SE
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unenhanced T1-weighted SE
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted SE
Number of subjects: 21
Study: 1770553

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7037160

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 0
Study: 29124388

Group type: EXPERIMENTAL
Intervention: Olive pomace-enriched biscuit (OEP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Isoenergetic control (CTRL)
Number of subjects: 62
Study: 29168028

Group type: EXPERIMENTAL
Intervention: Systemic administration of steroids (prednisolone intravenously followed by methylprednisolone orally)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intratympanic administration of methylprednisolone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined administration of systemic and intratympanic steroids
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified as a separate group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Younger patients (under 60 years old)
Number of subjects: 102
Study: 27482008

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study: 24485548

Group type: EXPERIMENTAL
Intervention: Two doses of MMRV
Number of subjects: 5803

Group type: EXPERIMENTAL
Intervention: MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group)
Number of subjects: 5803

Group type: COMPARATOR
Intervention: Two doses of MMR (control group)
Number of subjects: 5803
Study: 22077187

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with mothers
Number of subjects: 37

Group type: COMPARATOR
Intervention: Skin-to-skin contact (SSC) with fathers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with either parent
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interaction with mothers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interaction with fathers
Number of subjects: 37
Study: 20923288

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (performance feedback, small-group teaching seminars, and posters)
Number of subjects: 7901

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 7901

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 7901
Study: 18600386

Group type: EXPERIMENTAL
Intervention: 14-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Number of subjects: 275

Group type: COMPARATOR
Intervention: 7-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, bismuth subcitrate, doxycycline, metronidazole)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Follow-up after quadruple therapy
Number of subjects: 275
Study: 16077384

Group type: EXPERIMENTAL
Intervention: Ginsenosides compound (1.35 mg/kg intravenously before and throughout cardiopulmonary bypass)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 11836266

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d plus KCl placebo)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl/d)
Number of subjects: 9
Study: 9709845

Group type: EXPERIMENTAL
Intervention: Normal hip joints
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Acetabular dysplastic hip joints
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rotational acetabular osteotomy (RAO)
Number of subjects: 161
Study: 7836249

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Direct PTCA to left anterior descending artery
Number of subjects: 100
Study: 2901566

Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium ('Imuthiol') 10 mg/kg body weight given orally once a week
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ditiocarb sodium ('Imuthiol')
Number of subjects: 83
Study: 31738283

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (5 ml of 30% dextrose, 4 ml of saline, and 1 ml of 2% lidocaine mixture)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (9 ml of saline and 1 ml of 2% lidocaine mixture)
Number of subjects: 30
Study: 29154813

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 1230
Study: 26946985

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/d
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control arm (erlotinib alone 150 mg/d)
Number of subjects: 147
Study: 23892583

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Diet-Exercise
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study: 22538152

Group type: EXPERIMENTAL
Intervention: 5 mm needle with 20 U insulin diluent
Number of subjects: 56

Group type: COMPARATOR
Intervention: 8 mm needle with 20 U insulin diluent
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5 mm needle with 60 U insulin diluent
Number of subjects: 56

Group type: COMPARATOR
Intervention: 8 mm needle with 60 U insulin diluent
Number of subjects: 56
Study: 20016247

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate method for collection of stratum corneum samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanically removed SC samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate method
Number of subjects: 0
Study: 18172627

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study: 15993115

Group type: EXPERIMENTAL
Intervention: Syncage‐C filled with autologous cancellous bone grafts and CSLP (cage group, n=27)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Autologous tricortical iliac crest bone graft and CSLP (bone graft group, n=26)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cage group
Number of subjects: 53
Study: 12881395

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXA) 130 mg/m² over 2 hours
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5-fluorouracil (OXFU) 1000 mg/m²/day, continuous intravenous infusion, days 1-4
Number of subjects: 54
Study: 10526733

Group type: EXPERIMENTAL
Intervention: Problem-based learning educational program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study: 8663944

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (100 micrograms/d in each nostril)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray (100 micrograms in each nostril every 12 hours)
Number of subjects: 60
Study: 1451923

Group type: EXPERIMENTAL
Intervention: 10 mg/day astemizole for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg/day loratadine for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 120 mg/day terfenadine forte for 3 days
Number of subjects: 6
Study: 6421391

Group type: EXPERIMENTAL
Intervention: Polyadenylic‐polyuridylic acid
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study: 29500021

Group type: EXPERIMENTAL
Intervention: Digital information
Number of subjects: 103

Group type: COMPARATOR
Intervention: Printed information
Number of subjects: 103
Study: 26583940

Group type: EXPERIMENTAL
Intervention: 2 ml of 30% sucrose (group I, n=45)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS) (group II, n=45)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combined sucrose and NNS (group III, n=45)
Number of subjects: 180

Group type: COMPARATOR
Intervention: None (group IV, n=45)
Number of subjects: 180
Study: 24412523

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg orally twice a day)
Number of subjects: 60
Study: 22509738

Group type: EXPERIMENTAL
Intervention: SRP + Er:YAG laser (10 hz, 30 mJ/pulse, 1 min per pocket, apico‐coronal direction in parallel paths with 30 degree angle tips, under water irrigation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SRP + systemic metronidazole
Number of subjects: 27

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 27
Study: 19841042

Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acid intake (mO-3FA)
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for weight loss
Number of subjects: 2397
Study: 18045264

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 15644067

Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg) + Selegiline (5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 32
Study: 12396241

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amine/stannous fluoride
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 21
Study: 10540928

Group type: EXPERIMENTAL
Intervention: Diazepam (0.7 mg/kg body weight)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg body weight)
Number of subjects: 90
Study: 7762650

Group type: EXPERIMENTAL
Intervention: GIP (1 pmol.kg‐1.min‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GLP-I‐(7‐‐36) amide (0.3 pmol.kg‐1.min‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CCK-8 (0.5 pmol.kg‐1.min‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl‐1% human serum albumin)
Number of subjects: 9
Study: 2324921

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Acetaminophen 500 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 7002707

Group type: EXPERIMENTAL
Intervention: Autologous intestinal contents infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Artificial bile acid solution infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bile acid concentrations
Number of subjects: 21
Study: 30489441

Group type: EXPERIMENTAL
Intervention: Self-care breath training program (30-min training followed by 15 min twice daily for 6 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Self-care breath training program
Number of subjects: 23
Study: 25356570

Group type: EXPERIMENTAL
Intervention: D-cycloserine plus computer-based cognitive training (CT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo plus computer-based cognitive training (CT)
Number of subjects: 34
Study: 23117349

Group type: EXPERIMENTAL
Intervention: Home-based individually tailored balance, strengthening and walking exercise programme (physiotherapist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home-based education programme (control)
Number of subjects: 40
Study: 20689457

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution (P)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mouth rinsing 6.4% CHO (R)
Number of subjects: 10
Study: 19700798

Group type: EXPERIMENTAL
Intervention: Curd (Indian dahi)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leaf protein concentrate (LPC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (WHO recommended diet for severe malnutrition)
Number of subjects: 80
Study: 16676077

Group type: EXPERIMENTAL
Intervention: Antithrombin (30,000 IU) over four days without concomitant heparin
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Antithrombin (30,000 IU) over four days with concomitant heparin
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Antithrombin (30,000 IU) without concomitant heparin
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Antithrombin plus concomitant heparin
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Antithrombin with or without concomitant heparin
Number of subjects: 2314
Study: 15290119

Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD brain SPECT in HT patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: 99mTc‐ECD brain SPECT in NTNG patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: 99mTc‐ECD brain SPECT in healthy controls
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mean Asymmetry Index (AI) in HT patients
Number of subjects: 16
Study: 11373409

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin at 0.04 units/min for 16 hrs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as patients receiving catecholamines)
Number of subjects: 16
Study: 9413849

Group type: EXPERIMENTAL
Intervention: Polypropylene hollow‐fibre membrane (group 1; 2.2 m2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polypropylene flat‐sheet membrane (group 2; 3.1 m2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silicone envelope membrane (group 3; 3.5 m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 1 (Polypropylene hollow‐fibre membrane)
Number of subjects: 30
Study: 8481249

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.2 mg intravenously)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (1 ml saline solution)
Number of subjects: 61
Study: 3325934

Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 400 mg ciprofloxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin orally
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g daily for seven days
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 341
Study: 30568484

Group type: EXPERIMENTAL
Intervention: Diaphragm Training (DT group, n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Complex Training (Control group, n=21)
Number of subjects: 52
Study: 27449926

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis (B. infantis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24398898

Group type: EXPERIMENTAL
Intervention: Training with continual visual feedback of frequency error
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training with elastic bands attached to the lever (resonant system)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Training without resonance and no feedback
Number of subjects: 30
Study: 23139388

Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 0
Study: 20547904

Group type: EXPERIMENTAL
Intervention: 9 additional months of oral valganciclovir (n = 70)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 136
Study: 18237364

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 2

Group type: COMPARATOR
Intervention: N-of-1 trials (gabapentin vs placebo)
Number of subjects: 2

Group type: COMPARATOR
Intervention: N-of-1 trials (celecoxib vs paracetamol)
Number of subjects: 2
Study: 16627573

Group type: EXPERIMENTAL
Intervention: Water-only starvation (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate/high-fat diet (LC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed carbohydrate diet (C)
Number of subjects: 0
Study: 14676071

Group type: EXPERIMENTAL
Intervention: alefacept, 7.5 mg, in both courses (cohort 1)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: alefacept, 7.5 mg, in the first course and placebo in the second course (cohort 2)
Number of subjects: 553

Group type: COMPARATOR
Intervention: placebo in the first course and alefacept, 7.5 mg, in the second course (cohort 3)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: alefacept (both cohorts 1 and 2)
Number of subjects: 553
Study: 10721963

Group type: EXPERIMENTAL
Intervention: Nuclear opacity (particularly severe nuclear opacity)
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Mixed opacities with nuclear
Number of subjects: 2520
Study: 8981145

Group type: EXPERIMENTAL
Intervention: Oocytes exposed to spermatozoa for 1 hour (Group A)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oocytes exposed to spermatozoa for 16 hours (Group B)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Oocytes exposed to male factor spermatozoa for 1 hour
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oocytes exposed to male factor spermatozoa with standard culture interval
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Oocytes exposed to normal spermatozoa for 1 hour
Number of subjects: 167